Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MAFFO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DTPA-hMN-14-700DX
|
|||||
| Synonyms |
MN-14-700DX; Photodynamic therapy (Immunomedics)
Click to Show/Hide
|
|||||
| Organization |
Immunomedics, Inc.; Gilead Sciences, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.5
|
|||||
| Antibody Name |
Labetuzumab
|
Antibody Info | ||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
|
Antigen Info | ||||
| Payload Name |
IRDye 700DX
|
Payload Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Sarotalocan
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.